可必特联合孟鲁司特钠治疗小儿支气管哮喘急性发作的临床研究

目的探讨可必特联合孟鲁司特钠治疗小儿支气管哮喘急性发作的临床疗效及安全性。方法 105例支气管哮喘患儿随机分为治疗组、对照组。两组均给予吸氧,抗感染,化痰平喘,营养支持,维持水电解质平衡等基础治疗。对照组在基础治疗上加用布地奈德混悬液雾化吸入,2次/d。治疗组在基础治疗上给予孟鲁司特钠咀嚼片每晚顿服,同时联合可必特雾化吸入治疗,2次/d。两组疗程均为7~10d。结果治疗组症状、体征缓解明显早于对照组,治疗组肺功能改善优于对照组;治疗组总有效率90.57%,对照组为73.08%,明显高于对照组;且治疗组住院天数亦少于对照组。两组比较差异有统计学意义(P<0.05)。结论可必特联合孟鲁司特钠治疗小儿支气管哮喘急性发作临床疗效确切,安全性高,值得临床推荐。

Clinical Observation for Compound Ipratropium Bromide Aerosol Combination Montelukasta in the Treatment of Acute Asthma Exacerbation in Children

Objective To study the efficacy and security of compound Ipratropium Bromide Aerosol combination Montelukasta in the treatment of acute asthma exacerbation in children. Methods 105 patients were randomLy divided into the treatment group and the control group. The two groups were all given the conventional treatment. On the basis of conventional treatment, the control group were treated by inhaled budesonide, 2 times/d, and the treatment group were given compound Ipratropium Bromide Aerosol combination Montelukasta. The courses of treatment were 7-10d. Results The symptom, body advertises for to alleviate early at the matched control, the lung function of the treatment group improves a better than matched control. The total effective rate for treatment and control was separately 90.57% and 73.08%, that of the treatment is more obviously high than the control.And the hospitalized number in the treatment group was Less than that of the control. Conclusion Compound Ipratropium Bromide Aerosol combination Montelukasta used for treating the acute asthma exacerbation in children is favourable and safe.